Breast Cancer Clinical Trial
Official title:
Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow
Patient-assisted compression (PAC) allows the patient to participate in controlling the amount of compression force during mammography and is a personalized approach that has demonstrated successful reduction in discomfort experienced during mammography. General Electric Healthcare's Senographe Pristina, an innovative mammography platform that provides both two-dimensional (2D) and three-dimensional (3D) imaging capabilities, offers both standard and patient-assisted compression modes. This study will evaluate image quality and clinical workflow as it relates to use of PAC with the Senographe Pristina 3D.
The study population will consist of adult asymptomatic women presenting for screening 2D
mammography. One breast of each subject will be identified as the "breast of interest," which
will undergo study-specific 3D imaging consisting of two-view (craniocaudal and mediolateral
oblique) PA compression and image acquisition, followed by two-view technologist-controlled
(TC) compression and image acquisition. The breast of interest will be randomly assigned to
either the first breast imaged during the exam or the second breast imaged. TC compression
and imaging, and procedures performed on the subject's other breast will be conducted per
standard of care.
Following image acquisition, 3D image quality evaluation will be conducted by Mammography
Quality Standards Act-qualified readers. Prior to the reading session, images will be
de-identified and the following information will be removed from the DICOM header to blind
readers to the compression mode used during acquisition: time stamp, compression force, and
breast thickness. The image sets will also be randomized for presentation during the image
attribute reviews. Two (2) readers will evaluate each PAC and TC compression image set
collected from each subject's breast of interest and assess the acceptability of image
attributes, as defined in the Guidance for Industry and FDA Staff - Class II Special Controls
Guidance Document: Full-Field Digital Mammography System (2012). A third reader will provide
adjudication, if there is disagreement for a given image set's overall clinical image
quality.
Workflow data, including the incidence of technologist intervention during acquisition and
need for repeat image acquisition, will also be collected.
The proportion of PAC image sets that are of equal or higher acceptability than TC image sets
will be calculated. A 95% confidence interval will be calculated using asymptotic method with
continuity correction. The proportion of image sets indicated for repeated image acquisition
when using PA mode or TC mode will be summarized. Other endpoint data will be summarized
using descriptive statistics. No statistical hypothesis is being tested in this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |